Serial Measurement of Capillary Blood Lactate in the Management of Sepsis

NCT02180399 | Completed

• 1 other identifier: 6031
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

Determination of capillary lactate by using "point-of-care" technique is accessible, fast and allows to quantify the circulatory and metabolic dysfunction caused by sepsis. Compared to conventional assay techniques in arterial blood, capillary assay technique may have an increased susceptibility to metabolic alterations induced by sepsis in its initial stages. This increased sensitivity is not necessarily relevant in the management of the most serious patients for whom the diagnosis is obvious, but it could be very useful in patients for whom a diagnosis of severe sepsis or shock have not yet been adopted, particularly to help better identify patients who would require intensive management and avoid the installation of these serious disorders.

Conditions

Sepsis

Keywords

Sepsis; Capillary blood lactate; Serial measurement of capillary

Outcome Measures

Primary Outcomes (1)

• measurement of capillary blood lactate

  72 hours after inclusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients over age 18 with an acute systemic inflammatory response syndrome array of presumed infectious not yet been treated.

You may qualify if:

• Age ≥ 18 years
• Installation without any plausible explanation of at least one of the following clinical criteria:
• Chills, fever, mottling, respiratory rate\> 20/min; Sat02 \< 90% or \> 94% with more than 4l O2, heart rate \> 90/min,systolic blood pressure \< 100 mmHg or 40 mmHg lower compared with normal values, Glasgow coma score \< 14. or: .a combination of two (or more) of clinical and laboratory criteria for sepsis.
• Signed informed consent form

You may not qualify if:

• Need in its current treatment of aerosol administration of beta agonists at a frequency greater than one per 8 hours;
• Targeted therapeutic measures have already stated for more than 60 minutes;
• Diagnosis other than Sepsis;
• Malignant neoplasm or other progressive disease and expected survival was less than 3 months.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (2)

SERVICE DE MED. INTERNE - DIABETE ET MALADIES METABOLIQUES, 1-place de l'Hôpital

Strasbourg, 67091, France

Location

Service de Médecine Interne - Clinique Médicale B

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Emmanuel ANDRES, MD, PhD

  University Hospitals of Strasbourg

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 5, 2014
• First Posted: July 2, 2014
• Study Start: February 1, 2014
• Primary Completion: September 30, 2017
• Study Completion: September 30, 2017
• Last Updated: September 5, 2025

Record last verified: 2025-09

Locations

FR (2)